Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines
Historically, vaccine development has been heavily supported by government and public institutions. On the other hand, private biopharmaceutical companies have played a significant role in the development of innovative new therapies using novel pharmaceutical technologies. COVID-19 vaccines using ne...
Saved in:
| Main Author: | Ryo Okuyama |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2001-6689/12/4/25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Strategic aspects of staffing industrial biopharmaceutical companies
by: A. S. Glazkova, et al.
Published: (2020-01-01) -
National Granted Programs and Public Funds for Biopharmaceutical Startups in Japan
by: Ryo Okuyama
Published: (2025-06-01) -
ELEMENTS CONCERNING THE INSTITUTIONAL FRAMEWORK OF PUBLICPRIVATE PARTNERSHIP
by: Florina POPA
Published: (2018-05-01) -
Analysis of the barriers within and outside the organization of public-private partnership in Iran
by: Vali Rahmani, et al.
Published: (2018-11-01) -
Features of the Institutional Environment of Public-Private Partnership in Russia: Regional Aspect
by: N. S. Moguchev, et al.
Published: (2021-02-01)